| Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology |
38 |
| Psychedelics and the essential importance of context |
33 |
| Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors |
29 |
| 4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial |
24 |
| Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications |
23 |
| British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update |
20 |
| Characteristics of deaths associated with kratom use |
17 |
| Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia |
15 |
| Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance |
15 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use |
14 |
| Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory |
14 |
| Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats |
13 |
| Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts |
13 |
| The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption |
13 |
| Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression |
13 |
| Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders |
12 |
| The Australian drug harms ranking study |
12 |
| Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial |
11 |
| The putative lithium-mimetic ebselen reduces impulsivity in rodent models |
11 |
| Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression |
11 |
| Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice |
10 |
| Antipsychotic drug use and pneumonia: Systematic review and meta-analysis |
10 |
| Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-5417 a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants |
10 |
| Lithium treatment for unipolar major depressive disorder: Systematic review |
9 |
| Silymarin and silymarin nanoparticles guard against chronic unpredictable mild stress induced depressive-like behavior in mice: involvement of neurogenesis and NLRP3 inflammasome |
9 |
| Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder |
9 |
| It feels real: physiological responses to a stressful virtual reality environment and its impact on working memory |
9 |
| Polymorphisms in CYP1A CYP2C9 and ABCB1 affect agomelatine pharmacokinetics |
9 |
| Adjunctive minocycline for major mental disorders: A systematic review |
8 |
| Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study |
8 |
| Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing |
8 |
| What are the psychological effects of using synthetic cannabinoids? A systematic review |
8 |
| Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study |
8 |
| A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor |
8 |
| Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity |
7 |
| Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 4-methylenedioxypyrovalerone in the rat |
7 |
| The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression |
7 |
| The relationships of classic psychedelic use with criminal behavior in the United States adult population |
7 |
| Regulation of adenosine A(2A) receptor gene expression in a model of binge eating in the amygdaloid complex of female rats |
7 |
| Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders |
7 |
| Studies into the anxiolytic actions of agomelatine in social isolation reared rats: Role of corticosterone and sex |
7 |
| Female psychopharmacology matters! Towards a sex-specific psychopharmacology |
7 |
| The effect of ketamine on the consolidation and extinction of contextual fear memory |
7 |
| Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis |
7 |
| Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders |
7 |
| A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity |
7 |
| Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation |
6 |
| Methylphenidate enhances implicit learning in healthy adults |
6 |
| Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets |
6 |
| Buprenorphine alone or with naloxone: Which is safer? |
6 |
